S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
66,000% upside on tiny biotech? (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
66,000% upside on tiny biotech? (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
66,000% upside on tiny biotech? (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
66,000% upside on tiny biotech? (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

$576.29
+4.98 (+0.87%)
(As of 02/23/2024 08:53 PM ET)

IDEXX Laboratories Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$591.50
2.64% Upside
High Forecast$655.00
Average Forecast$591.50
Low Forecast$460.00
TypeCurrent Forecast
2/26/23 to 2/26/24
1 Month Ago
1/27/23 to 1/27/24
3 Months Ago
11/28/22 to 11/28/23
1 Year Ago
2/26/22 to 2/26/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$591.50$573.63$548.14$514.75
Predicted Upside2.64% Upside22.78% Upside22.52% Upside13.87% Upside
Get IDEXX Laboratories Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.


IDXX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEXX Laboratories Stock vs. The Competition

TypeIDEXX LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside2.64% Upside1,898.10% Upside7.54% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$600.00 ➝ $630.00+11.83%
2/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$605.00 ➝ $655.00+14.25%
1/30/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$525.00-1.33%
1/17/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$500.00 ➝ $650.00+25.68%
1/5/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
12/7/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$602.00+15.42%
10/30/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$500.00 ➝ $460.00+17.57%
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$590.00 ➝ $600.00+16.84%
8/2/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$610.00+14.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:56 AM ET.












IDXX Price Target - Frequently Asked Questions

What is IDEXX Laboratories's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for IDEXX Laboratories stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for IDXX. The average twelve-month price prediction for IDEXX Laboratories is $591.50 with a high price target of $655.00 and a low price target of $460.00. Learn more on IDXX's analyst rating history.

Do Wall Street analysts like IDEXX Laboratories more than its competitors?

Analysts like IDEXX Laboratories less than other Medical companies. The consensus rating score for IDEXX Laboratories is 2.67 while the average consensus rating score for medical companies is 2.67. Learn more on how IDXX compares to other companies.

Is IDEXX Laboratories being downgraded by Wall Street analysts?

Over the previous 90 days, IDEXX Laboratories's stock had 1 downgrade by analysts.

Does IDEXX Laboratories's stock price have much upside?

According to analysts, IDEXX Laboratories's stock has a predicted upside of 14.17% based on their 12-month stock forecasts.

What analysts cover IDEXX Laboratories?

IDEXX Laboratories has been rated by Barclays, BNP Paribas, JPMorgan Chase & Co., Piper Sandler, The Goldman Sachs Group, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:IDXX) was last updated on 2/26/2024 by MarketBeat.com Staff